Abstract

BackgroundFunctional disruptions by large germline genomic structural variants in susceptible genes are known risks for cancer. We used deletion structural variants (DSVs) generated from germline whole-genome sequencing (WGS) and DSV immune-related association tumor microenvironment (TME) to predict cancer risk and prognosis.MethodsWe investigated the contribution of germline DSVs to cancer susceptibility and prognosis by silicon and causal inference models. DSVs in germline WGS data were generated from the blood samples of 192 cancer and 499 non-cancer subjects. Clinical information, including family cancer history (FCH), was obtained from the National Cheng Kung University Hospital and Taiwan Biobank. Ninety-nine colorectal cancer (CRC) patients had immune response gene expression data. We used joint calling tools and an attention-weighted model to build the cancer risk predictive model and identify DSVs in familial cancer. The survival support vector machine (survival-SVM) was used to select prognostic DSVs.ResultsWe identified 671 DSVs that could predict cancer risk. The area under the curve (AUC) of the receiver operating characteristic curve (ROC) of the attention-weighted model was 0.71. The 3 most frequent DSV genes observed in cancer patients were identified as ADCY9, AURKAPS1, and RAB3GAP2 (p < 0.05). The DSVs in SGSM2 and LHFPL3 were relevant to colorectal cancer. We found a higher incidence of FCH in cancer patients than in non-cancer subjects (p < 0.05). SMYD3 and NKD2DSV genes were associated with cancer patients with FCH (p < 0.05). We identified 65 immune-associated DSV markers for assessing cancer prognosis (p < 0.05). The functional protein of MUC4 DSV gene interacted with MAGE1 expression, according to the STRING database. The causal inference model showed that deleting the CEP72 DSV gene affect the recurrence-free survival (RFS) of IFIT1 expression.ConclusionsWe established an explainable attention-weighted model for cancer risk prediction and used the survival-SVM for prognostic stratification by using germline DSVs and immune gene expression datasets. Comprehensive assessments of germline DSVs can predict the cancer risk and clinical outcome of colon cancer patients.

Highlights

  • Large-scale germline structural variants, especially deletion structural variants (DSVs), can affect gene expression with a partial or complete loss of gene function and increased cancer risk in patients [1, 2]

  • The causal inference model showed that deleting the CEP72 DSV gene affect the recurrence-free survival (RFS) of IFIT1 expression

  • As deep learning (DL) has improved the ability to predict inherited cancer genomic susceptibility, we focused on DL as an attention-weighted model with multilayer perceptrons (MLPs) [9], which can reveal the importance of each DSV for predicting cancer risk

Read more

Summary

Introduction

Large-scale germline structural variants, especially deletion structural variants (DSVs), can affect gene expression with a partial or complete loss of gene function and increased cancer risk in patients [1, 2]. The role of germline DSVs and DSV immune-related association tumor microenvironment (TME) in cancer risk and prognosis had not been sufficiently understood. As DL has improved the ability to predict inherited cancer genomic susceptibility, we focused on DL as an attention-weighted model with multilayer perceptrons (MLPs) [9], which can reveal the importance of each DSV for predicting cancer risk. We used the survival support vector machine (survival-SVM) for selecting the features of prognostic DSVs. Functional disruptions by large germline genomic structural variants in susceptible genes are known risks for cancer. We used deletion structural variants (DSVs) generated from germline whole-genome sequencing (WGS) and DSV immune-related association tumor microenvironment (TME) to predict cancer risk and prognosis

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call